News · 26 weeks53-42%
2026-03-012026-08-23
Mix2990d
- SEC Filings17(59%)
- Insider8(28%)
- Earnings2(7%)
- Analyst1(3%)
- Other1(3%)
Latest news
25 items- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 10-Q filed by Sanara MedTech Inc.10-Q - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRSanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Summary(1) ●Net revenue increased 9% to $28.1 million, compared to $25.8 million in the second quarter of 2025. ●Gross profit of $26.2 million, or 93% of net revenue, compared to gross profit of $23.9 million, or 92% of net revenue, in the second q
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECAmendment: Sanara MedTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - Sanara MedTech Inc. (0000714256) (Filer)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- ANALYSTSanara MedTech downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Sanara MedTech from Buy to Neutral and set a new price target of $35.00
- SECSEC Form 425 filed by Sanara MedTech Inc.425 - Sanara MedTech Inc. (0000714256) (Subject)
- SECSanara MedTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sanara MedTech Inc. (0000714256) (Filer)
- PRMIMEDX Announces Second Quarter 2026 Operating & Financial ResultsReports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the second quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter, we delivered another strong performance in our Surgical franchise, with 15% year-over-year revenue growth balanced across our sheet and particulate products. Our sustained momentum in several Su
- PRMIMEDX to Acquire Sanara MedTechTransformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") and Sanara MedTech Inc. ("Sanara," "Sanara MedTech") (NASDAQ:SMTI) today a
- SECSEC Form 8-K filed by Sanara MedTech Inc.8-K - Sanara MedTech Inc. (0000714256) (Filer)
- INSIDERDirector Tanzberger Eric D was granted 5,308 shares, increasing direct ownership by 30% to 22,966 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Major Eric D was granted 4,846 shares, increasing direct ownership by 52% to 14,232 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Ortwein Sara N was granted 4,616 shares, increasing direct ownership by 22% to 25,415 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Nixon Ronald T was granted 4,154 shares, increasing direct ownership by 6% to 68,196 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
- INSIDERDirector Desutter Robert Andrew was granted 5,539 shares, increasing direct ownership by 24% to 28,740 units (SEC Form 4)4 - Sanara MedTech Inc. (0000714256) (Issuer)
SMTI FAQ
6 questionsWhat does Sanara MedTech Inc. do?
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes...Where does SMTI stock trade?
Sanara MedTech Inc. (SMTI) is listed on NASDAQ.What sector and industry is SMTI in?
Sanara MedTech Inc. operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about SMTI?
Sanara MedTech Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $3500.00 price target on 2026-07-30. Recent price targets range from $3200.00 to $4500.00.What companies are similar to SMTI?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SMTI side-by-side with any of them on Quantisnow.How can I track SMTI on Quantisnow?
Quantisnow aggregates Sanara MedTech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SMTI to receive live email and push alerts on every new disclosure.